Reddit Posts
I think Abbott ($ABT) is a strong future play soon, and here is why
DexCom stock slips despite Q1 beat and guidance raise (NASDAQ:DXCM)
Query - What has more impact on an index like NASDAQ-100?
Super Bowl ads boost sales of drugs, yet only two companies advertising this year (DXCM)
Hot Stocks: SPOT climbs on activist interest; DXCM, AYX rise on earnings news; MGA drops
$BLGO BioLargo reports another record quarter of strong growth and believes this is just the beginning of massive growth in environmental solutions
If I plan to invest in IoT, should I still add FAANG stocks?
If I plan to invest in IoT, should I still add FAANG stocks?
#afterhours #watchlist 09/13 $LIFE - old news, $DXCM - old news. Any trading ideas? Welcome in comments!
#afterhours #watchlist 09/13 $LIFE - old news, $DXCM - old news. Any trading ideas? Welcome in comments!
I am a Type 1 Diabetic, And I'm Extremely Bullish on SENS
I can’t stand when $SENS is labeled a “meme-stock”
SENS (32% shorted) can be a 10x candidate from here. Warning extreme DD, requires wrinkled brain.
$SENS - Fuck Diabetes & Fuck The Shorts
Putting my two Sense in to get a dollar back
Putting in my two sense to get a dollar back
Who will be the big winner in the continuous glucose monitoring (CGM) market? Dexcom or Abbott Labs?
Who will be the big winner in the continuous glucose monitoring (CGM) market? Dexcom (DXCM) or Abbott Labs (ABT)?
Will Dexcom (DXCM) be a big winner in the continuous glucose monitoring (CGM) market?
$SENS in position to sell lots of CGMs in 2022 and beyond
A Friendly Reminder About SENS and some new information
A Friendly Reminder About SENS and some new information
🚀🚀Why $SENS is a better bet than $DXCM 🚀🚀
My Last Yolo Update Part 3: $SENS on the rise past $2 and new shares issued to insiders
Mentions
I bought NVDA at split-adjusted $3.50. How do I continue to hold it? I look at everything that made me buy it in the first place. Others I have let go. Rode DXCM up and sold out. Same with CRWD and MU. I don’t need to sell at the top. I’ll take the profits if I think the money would be better elsewhere.
I’m already very long on SYK, RMD and DXCM. ADBE has fallen so far it’s now on my watchlist. I’ve never seen the appeal of MSFT, and still don’t. But I invest in stability. And at the moment the world is more unstable than it has ever been in my lifetime. I’ve done some judicious trimming, and have a decent amount set aside for when I feel comfortable buying again. But I’m not buying anything right now.
medical tech. $GH, $DXCM, $INSP, $TMDX
Yep, same with TOST, ROKU, TLWO, DXCM, ANET and AMAT. Bought at the bottom
Wish DXCM had more daily volume
I see you made a post for DXCM. Is GH a new one you like?
in short - GH will be the near monopoly in cancer screening few years from now and DXCM is comically undervalued 1 year price target
I commented in the last thread and was openly skeptical. I’ve got to give you credit, you nailed that one. Investing in health-related companies makes me nervous, but I’ll at least take a look at these two. Any thoughts on why you’re optimistic on GH and DXCM? Timeframes for your price targets?
Some DD on Dexcom via [Magic Signal](https://magicsignal.app/) Key Highlights: Q4 2025 preliminary revenue reported at $1.26B, up 13% year-over-year (YoY), with international segment growth outpacing domestic performance 2026 guidance reflects 11-13% expected revenue growth and notable margin expansion expectations Barclays downgraded the stock to underweight, setting a $71 price target, contrasting with the broader bullish Street consensus Insider buying (COO acquisition of 18,200 shares) signals executive confidence Analyst sentiment remains broadly positive despite pockets of caution; average price target $86.30, with majority Buy/Outperform ratings Valuation perspectives remain mixed, with upside in Street consensus but lower DCF estimates creating ambiguity Put/Call Ratio: 0.57 (Bullish skew) Options Volume: Call volume up 122%, Put volume up 34% versus average—heavy bullish options activity Open Interest (OI): Call OI (59.1% of total) remains robust despite slight decrease, Put/Call OI ratio 0.69 supports bullish stance Implied Volatility: 30-day IV at 59.8% (about mid-range), suggesting moderately elevated expectations for price movement Key Technical Interpretations: Momentum indicators (MACD, price above 20-day SMA) support a bullish bias RSI near 70 signals approaching overbought levels, raising short-term caution for potential pullbacks or consolidation Options market positioning and increased call volume reflect heightened market optimism and potential near-term catalysts Market Analysis: Healthcare sector remains resilient: CGM adoption is expected to accelerate globally, driven by increased diabetes prevalence and digital health integration International growth outpaces U.S. market: International revenues rose 18% YoY, positioning DXCM for market share gains abroad Mixed analyst sentiment aggregates to a positive bias: Despite a recent underweight call from Barclays, the consensus target ($86.30) implies material upside Valuation discrepancies: Gap between Street price targets and DCF models introduces some risk of volatility in the event of macro- or sector-driven corrections Investment Outlook: Short-term (1-3 months): BULLISH | Confidence: 65% Supported by strong technical momentum, options market bullishness, and recent earnings beats Potential catalyst: Upcoming J.P. Morgan Healthcare Conference and positive post-earnings revisions Risks: RSI near overbought and Barclays downgrade could trigger short-term profit-taking Medium-term (3-12 months): BULLISH | Confidence: 75% Guidance for margin expansion and international growth, combined with continuous product enhancements, bode well for medium-term appreciation Street consensus and executive insider buying reinforce the positive outlook Risks: Valuation divergence and sector rotation could moderate gains Risk Assessment: Valuation uncertainty: Major discrepancy between DCF-based fair value ($53.26) and Street consensus ($86.30) increases risk of volatility if expectations reset Analyst downgrade overhang: Barclays’ underweight rating and conservative price target may temper broader market enthusiasm in the near term Margin pressure risk: Despite guided improvements, DXCM must execute cost controls amid competitive pressure to deliver on margin expansion Regulatory or product setback: Any adverse clinical, regulatory, or product quality events (especially with new product launches like G7) could impact near-term revenue and sentiment Sector volatility: Healthcare sector is sensitive to changes in reimbursement policies, macroeconomic shocks, and competitive disruption
DXCM and NVO - just mad I didn't sell when they were all time high and there's no reason why they can't rebound but yet here we are. Just in denial don't want to realize my losses.
I typically do LEAPS with 30% or more dips. Strong fundamentals. I am currently in 4 dips: TEAM, FI, STZ and DXCM. Really considering MOH. Looking to add 2-3 more after Jan.
Well guess what analysts have also been saying? OPEN (Sell, target $1.42 - where is it now?), NOTE (Strong buy, target $26, where is it now?), DXCM (Strong buy, but keeps declining) amongst others. So don't follow these "analysis" blindly. Yes consider what they say, but for sure you should do your own research especially since you say you bought "several" shares at $300!
Check out DXCM if you want to see what the bottom of the S&P is doing
[$ADHC](https://x.com/search?q=%24ADHC&src=cashtag_click) [https://finance.yahoo.com/news/adhc-fda-review-glucoguards-breakthrough-130000710.html](https://t.co/nqTSQOv43W) [https://finance.yahoo.com/news/glucoguard-receives-scope-sow-proposal-100000878.html](https://t.co/hVRSoCdPiH) [https://finance.yahoo.com/news/dr-kunal-sur-phd-co-120000557.html](https://t.co/XxOvGuadiV) [https://finance.yahoo.com/news/glucoguard-receives-43-million-enterprise-130000155.html](https://t.co/QEp121uk5k) [https://x.com/buffalofireside/status/1980033185002963352](https://x.com/buffalofireside/status/1980033185002963352) [https://finance.yahoo.com/quote/DXCM/?p=DXCM](https://t.co/pSeiiiLHv2)
DXCM and KVUE shares. FLY shares too, but risky.
$DXCM Cash generating machine. Near 52 week low
I may just close it near break even. I think big news incoming for DXCM by year end. Trying to build a position
this sub is so boring these days, basically bogleheads v2 put a significant port of your money into GH i posted about TNDM in wsb and other subreddits when it was $4 in 2017 and told everyone to hold into a price target of $60. it reached $120. i 30xed my net worth on that one play and have since then consistently outperformed the market by investing solely in confident medtech plays (DXCM, ALGN, ABMD, ISRG, PEN) etc my most recent play i posted about on reddit was TMDX at 60 and it short squeezed all the way to $150 on stellar earnings. happy to provide proof if you want. i have an edge because i used to work for a hedge fund so i know how to build a thesis and act on it. my next double bagger is GH, PT of $100 within a year, could 4x within 3 years. they will have a near monopoly in cancer screening 5 years from now enjoy it if you trust the process
I sold the shares due to getting called away with CC but I like DXCM if it goes back to the 50s/60s, Bros around $48/$50, AAP around $48, CPB in the $30s, $KHC around $26.50 and NKE around $58/$60
Added some $DXCM calls into earning next week - they report Weds after the close. Similar setup to $TTD Not saying DeJaVu coming but maybe a nice premium build into the report - and possible oppty to take some off before they report
# Healthcare * **Winners:** **VRTX** (+3.38%) led gains, reflecting robust performance or favorable news. * **Losers:** **LLY** (-6.45%) and **DXCM** (-9.19%) faced losses. * **Trend:** Mixed results as investors balanced drug innovation against other headwinds.
Which of these would you play as a value swing trade stock? Which ones do you think have more room to fall? I'm looking to get some January call options on some of these? Any others that you think are screaming buys? FSLR - I must admit I don't know much abut them EL - this one is risky, but look at nike and starbucks, they went back $20/$30 after their 5 year lows. DXCM - a defensive healthcare stock in these uncertain times. NVO - doesn't seem to have much going for it, but it has appeared to bottom again, and may be a stock the market rotate into MDB - Ive beaten myself up everytime I didn't buy the dip on this stock. DECK - the hypergrowth phase is over, do you guys think hoka shoes are just a phase? I don't see nike shoes as any more attractive tbh PEP - can they stay this cheap forever? I don't like junk food stocks though
The general idea—to make a few small investments in individual companies—is, I would say, a good one. But you’re picking the wrong companies. You’re picking companies based on what everyone is talking about online, and that’s bad. Those companies are by definition old news. I’m old, so take this or leave it. But the best investments I made when I was young were based on my own preferences, or on those of my friends. Twenty years ago everyone said Apple was doomed. But I loved their products, so I bought some AAPL. I liked EA’s games, and i liked shopping at COST and ROST. I’m not diabetic, but a friend who is diabetic talked about her new DXCM glucose monitor so enthusiastically I bought some shares. And over a few decades these all turned out to be good investments, much better than most of the stocks people were boosting online in 2005 or so. As a young person you know what you like, and other young people probably like those same things. Those are things that are new, and likely to grow in the coming years. And those are things old farts like me haven’t heard of. Watch for those things and when you see them invest in them.
I got DXCM 3/21 $65p lottos.
As a type 1 diabetic this is the first time I’ve even heard of this company. Something about a permanent (or 1 year) sensor under the skin doesn’t sit right with me. Dexcom and abbot have a duopoly in CGMs right now. They’re very easy to apply and change, and there’s usually no pain involved. These companies have the financial backing for new and improved products and don’t have as much risk. By the way, current CGMs have to be changed every 2 weeks. Not 3-6 months. The device SENS is proposing is entirely different from what abbot and Dexcom are doing. I have some shares in DXCM. From an investing perspective, I don’t buy speculative biomedical stocks. Learned my lesson a few years ago after buying a company called dermtech. The company had a great innovative product to screen for skin cancer. Long story short they burnt through cash and eventually delisted. You can make huge gains from speculative biomedical stocks but you’ll most likely lose.
Pretty sure it has to do with the announcement of the next AAPL event. They could be releasing a blood sugar app which would destroy DXCM.
Any reason for the DXCM movement that started at about 12pm on Tuesday? I'm holding an 11/15 $75C since before earnings that I thought was totally dead but it might end up getting back to only being down 50%, which I'll gladly take at this moment...
Can we keep track on his return so far he has TSM- 13 percent increase after earnings when he stated puts 0/1 ENPH- 15 percent decrease and he stated puts so win 1/2 VRT- dropped 4 percent and he stated Calls so no go there 1/3 DXCM- dropped two percent to essentially flat when he stated calls so 1/4 DECK- went up 12 percent at peak and he stated calls so 2/5 SKX- was up 9-10 percent pre market but if you had calls they essentially got crushed since it lost all its gains so if you had puts idek if you made any good money but it dropped 4 percent so 3/6?? Someone can correct me if I’m wrong that’s the corgi count so far this earnings szn. Think last earnings season he had a 70-75 percent hit rate but I didn’t really keep track like that to verify. Someone can correct me once again all I know in corgi we trust. If only I can pick one of his winners this time around😭.
Chat something very weird happened with my DXCM 3/21/25 $115 call. It dropped to 0.01 at 10am EST and went back up to 0.65 at 1pm EST. Surely a glitch right ? Or did some mofo get 65x gains in 3 hours ?
I guess CNBC was right... so much money on the sidelines. They're buying everything even if it only meets expectations like DXCM. I'm guessing that the market will keep going up until after earnings season.
DXCM killed all options.
DXCM 
DXCM going flat is ruining my straddle/db diagonal 😭
DXCM went positive 
If DXCM squeezes, will definitely be squeezing some nuts 
DXCM above Wed high 
Burn DXCM burn! Why are you going up
if DXCM is above 80 tomorrow, I'm buying a stelo
DXCM above VWAP, average short is now under water 👀
Why the fuck is DXCM almost green again. Back down to the pit of 60s for you
will my DXCM Nov. 1 80 call print? 
DXCM up 15% from post market lows, damn, should have bought the dip
DXCM took too much insulin, but it looks they ate a candy bar
What are all these posts about DXCM- Dicks Cum?
*tin foil hat on* DXCM is selling off like wildfire so Abbott can buy them out soon 
don't give me false hope DXCM
Will DXCM stay above $66 by open? Stay tuned for the next episode of “Selling OTM Puts”
Hoping DXCM does a v cuz I just bought that bottom 
Ahhh just woke up from a 36 hour nap, excited to see how my TSLA puts and DXCM calls are doing!
DXCM is gonna make me kms who’s got a play to make around $1500
DXCM dumping on good earnings nice
The same thing happened the last time DXCM reported earnings.
my DXCM call :( glad I kept it small
DXCM yikes. 
DXCM has dangerously low blood sugar.
LOL DXCM must've leaked. i just bought a few shares but damn
DXCM with the reversal 
Sold a $66p on DXCM for $1.20, gonna buy a nice dinner for me and the gf tomorrow night
someone is buying of DXCM calls, the premium just keeps increasing
Taking bets for DXCM ER 
What is the play on DXCM?
What yall think about DXCM ER? 🤔 Miss or Beat?
If y'all are bored, DXCM sold off 40 bucks last earnings..they report tonight
What is the play for tomorrow DXCM and EW earnings?
Ok gotcha I do like Microsoft, and nvidia. I am definitely getting some VOO. I currently have GL,NXT,DXCM,and F. I’m a big advocate for buying the dip and eating it out which is what I’m doing with DXCM and NXT right now. Not sure if I should just put it all in VOO since I have all of those.
DXCM calls. Thank me later.
MMM calls RTX calls TSLA straddle UPS straddle DXCM straddle Thnks for playing
Senseonics ($SENS) just received FDA approval for the first and only 365 day CGM. Even better versions in the pipeline. Going to beat out DXCM and Abbott in the coming years
You got almost 50k left. Put 25% into DXCM, 25% into HUM, 25% into DNUT, and 25% into ET. Then check on it in 5 years. Disclaimer: This is not financial advice. Hehe
GLP-1 agonists are definitely a factor, but CGMs are not usually available to people with type 2 diabetes who control their glucose levels with oral medication instead of insulin. The fact that DXCM's Stelo is available actually is complemented by the availability of GLP-1 agonists: it opens up the market for those not using insulin to watch their blood sugar using an OTC device (that's HSA/FSA eligible) while on GLP-1 agonists. Beyond that, [this report](https://accisstoolkit.haiweb.org/wp-content/uploads/2020/10/Estimate-of-Insulin-Use-in-Type-2-Diabetes1.pdf), which factors in the possibility of widespread adoption of GLP-1s still predicts a 20% increase in the number of people using insulin by 2030.
DXCM 20%, high-conviction stock, purchased most after the recent selloff.
Fedex calls might be the next play. I’ve been having 100%-300% returns on plays like this. NKE, DELL, DXCM
Thanks this is interesting. I will give it a trial and see and also look into DXCM
Another stock that I have bought into recently after a large dip is DXCM. Consistent revenue growth, growing free cashflows, think the reason for the dip is short term in nature. Been buying in around the blue highlighted area. https://preview.redd.it/hk1xme3xxpnd1.png?width=1740&format=png&auto=webp&s=8aac5775f7b7e02572dd5882e907662558acff92
of course. some people will chalk it up to being lucky but if you are well-seasoned in research (used to work at a hedge fund and equity research), you can find some golden opportunities I made a 3000% return on TNDM on a 100k investment, i even posted about it on this sub and wsb and helped some others make returns as well. Bought when it was $2 and sold at $60 then i doubled that with DXCM the following year basically did my DD and thought the insulin pump and diabetes market was heavily undervalued due to JNJ shutting down their insulin pump department (Animas) and their users needed to find a new home (either Medtronic or Tandem Diabetes) and TNDM had the best insulin pumps on the market despite being the smallest player - that was the opinion i concluded after scouring diabetes forums for months and gathering inputs. The original thesis was that even if TNDM were able to capture 20% of the new users, they would double their revenue expectations. Turns out, they actually 4xed and entered hyper growth and this was all my own research. there were no equity research reports to look up because all the analysts suspended coverage of the stock because it was on the path towards bankruptcy back in 2017 [https://i.imgur.com/hYo3482.png](https://i.imgur.com/hYo3482.png)
of course. some people will chalk it up to being lucky but if you are well-seasoned in research (used to work at a hedge fund and equity research), you can find some golden opportunities I made a 3000% return on TNDM on a 100k investment, i even posted about it on this sub and wsb and helped some others make returns as well. Bought when it was $2 and sold at $60 then i doubled that with DXCM the following year basically did my DD and thought the insulin pump and diabetes market was heavily undervalued due to JNJ shutting down their insulin pump department (Animas) and their users needed to find a new home (either Medtronic or Tandem Diabetes) and TNDM had the best insulin pumps on the market - that was the opinion i concluded after scouring diabetes forums for months. The thesis was that even if TNDM were able to capture 20% of the new users, they would double their revenue expectations. Turns out, they actually 4xed and entered hyper growth [https://i.imgur.com/hYo3482.png](https://i.imgur.com/hYo3482.png)
this stelo shit better work DXCM
Going into DXCM. It’s on a fire sale right now with 30% upside. Given their relationship with hospitals across US and global entry, as well as the release of a new otc product this week, they are ready to sore.
DXCM. 30% upside. Is the largest GCM in US and most accurate. It’s also the hospital choice. Picking it up while it’s on this fire sale and before they launch new overcounter product on Aug 30
DXCM stop dying of diabeetus 